News
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2026. Consolidated sales totaled €984 million in the first quarter of 2026.
Swipe to discover more
-
First-of-its-Kind Health Economic Analysis Shows Early Use of Fast Diagnostics in Sepsis Care Could Save Thousands of Lives and Reduce Health System Costs Across G7 Countries
bioMérieux, a world leader in in vitro diagnostics, announces the publication of a multi-country health economic analysis assessing the impact of deploying fast identification and antimicrobial susceptibility testing (ID/AST) early in the care pathway for patients with bloodstream infections at high-risk of sepsis. -
Always consider sepsis in the context of infection.
Patient associations across the globe are actively engaged in promoting this critical message to both healthcare professionals and the broader public. We met with Dr Rafael Moraes from ILAS, Melissa Mead from The UK Sepsis Trust and Thomas Heymann from Sepsis Alliance to learn more about their actions. -
Preserving the planet to protect health: our commitments and progress
Preserving the planet to protect health: our commitments and progress
Fully aware of today’s climate and environmental challenges, we are taking action to reduce the footprint of our activities, optimize the use of resources, and design increasingly responsible solutions. Since 2019, we have been committed to an ambitious environmental trajectory. Here is an overview of the concrete, measurable, and sustainable actions implemented by our teams around the world.
Enabling Decision-Making
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19
- ANTIMICROBIAL STEWARDSHIP
- SEPSIS
- FOOD SAFETY & QUALITY
- PHARMA QUALITY CONTROL
- COVID-19